Off-Label Prescribing

Jessica Shu, M.D., Ben Alencherry, M.D., and Ahman Rajpal, M.D.

Current treatment and management for osteoporosis >

Originally authored by Robert J. Pignolo, Jr., M.D., Ph.D., Professor of Medicine and Chair, Department of Internal Medicine, Division of Geriatric Medicine and Gerontology, Mayo Clinic Alix School of Medicine, Rochester, MN. Updated by Jessica Shu, M.D. and Ahman Rajpal, M.D., respectively Chief Resident and Assistant Professor, Department of Medicine, University Hospitals Cleveland Medical Center and Case Western Reserve University and Louis Stokes Cleveland VA Medical Center, and Ben Alencherry, M.D., Cardiovascular Fellow, Cleveland Clinic.

Low carb v. high protein diets >

John Merriman, M.D., Ben Alencherry, M.D., and Ahman Rajpal, M.D.

Treatment and management of T1DM. >

Kristen Welch, M.D., Ben Alencherry, M.D., and Nadine El Asmar, M.D.

Diagnosis and new treatments for PE. >

Christopher Kabrhel, M.D., M.P.H., Keith Albrektson, M.D., Ben Alencherry, M.D., and Jihane Faress, M.D.

January 17, 2020 | LOGIN | REGISTER | HELP |

Current Conference

Previous Conferences

Practice Guidelines and the Standard of Care in Medicine Preventing Racial Disparities in Health Status and Access to Health Care Medical Decision-Making on Behalf of Children and Adolescents Neuroethics Medical Confidentiality and Exceptions Containing Health Care Costs Direct-To-Consumer Genetic Testing The Genetic Information Nondiscrimination Act (GINA): What It Does and Does
Not Do and What It Means for Health Care Professionals Medical Research Ethics: Standards and Issues The Dark Side of Public Health The Truth About Medical Malpractice Consumer-Driven Health Care: Ethical and Legal Pitfalls The Ethics of Embryonic Stem Cell Research Striking Back Off-Label Prescribing See more...

Moderator's Bio Other Specialties Corrections Discuss

Off-Label Prescribing

CME credit is no longer available for this conference.

Maxwell J. Mehlman, J.D.

Prof. Mehlman reports no conflict of interest.

Release Date: 07/06/2004
Termination Date: 07/06/2007

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Learning Objectives

Upon completion of this Cyberounds^®, you should be able to:

Discuss the regulatory provisions governing off-label uses of drugs and medical devices
Discuss the ethical and legal issues raised by off-label use
List the arguments for and against promoting products for off-label purposes.

The information contained and displayed in this communication and within this Web site is provided solely for educational and discussion purposes. It does not constitute legal advice. No attorney-client relationship is formed by the transmission or receipt of this communication. No warranty, express or implied, is being offered. The actual law in the member-subscriber's jurisdiction may differ from that which is described in this communication. The member-subscriber should seek legal advice from his or her attorney on any matters related to the subject matter of this communication.

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

Health Law Disclaimer

Please click below to accept the terms of this CME activity